CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Liquidia Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Liquidia Corp
419 Davis Drive, Suite 100
Phone: (302) 636-5401p:302 636-5401 MORRISVILLE, NC  27560  United States Ticker: LQDALQDA
Business Summary
Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT-engineered inhaled dry-powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the board Stephen M.Bloch 63 10/1/2018 10/1/2018
Chief Executive Officer, Director Roger A.Jeffs 64 1/3/2022 11/18/2020
Chief Financial Officer, Chief Operating Officer MichaelKaseta 50 1/15/2024 11/1/2020
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Liquidia Technologies
Liquidia Technologies Inc.
Liquidia Technologies, Inc.
LQDA
RareGen, LLC

General Information
Number of Employees: 216 (As of 12/31/2025)
Outstanding Shares: 88,928,099 (As of 5/1/2026)
Shareholders: 1,000
Stock Exchange: NASD
Federal Tax Id: 851710962
Fax Number: (302) 636-5454
Email Address: info@liquidia.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 1, 2026